Abstract:1379 Objectives: Mutation of the leucine-rich repeat kinase 2 (LRRK2) gene is most common genic factor of Parkinson’s Disease (PD). Dopamine loss in striatumis linked to the disease severity of PD, and the deduction can be detected by dopamine transporter (DAT) positron emission tomography (PET). Alternation of DAT expression in G2019S-LRRK2 and LRRK2 knockout (KO) mice is critical to investigate the pathological influence of LRRK2 mutation in DAT. To explore this influence, 11C-CFT PET were performed in LRRK2 transgenic mice by small animal PET/CT.Methods: Static small animal PET/CT imaging was obtained for 20 min at 40 min post intravenous injection of 11C-CFT in G2019-LRRK2 transgenic mice (n = 4),the LRRK2-knockout mice (n = 6) and control C57BL/6 mice (n = 6). All CFT images were spatially normalized into PET template by using Pmod 3.5; then the voxel size of all images was scaled by 10 so that the default parameters in SPM12 could be applied and the images were smooth with a gaussian kernel. Finally, two-sample t test between G2019-LRRK2, LRRK2-knockout mice and C57BL/6 mice was performed respectively by SPM12 to explore the changed DAT expression in G2019-LRRK2, LRRK2-knockout mice. The statistical significance was set at p Results: Compared with control C57BL/6 mice, 11C-CFT uptake in right medial striatum and left posterior striatum of LRRK2-KO mice was significantly increased, while 11C-CFT uptake in right anterior ventral striatum of G2019S-LRRK2 mice was significantly decreased. Furthermore, the increased clusters of LRRK2-KO compared to G2019S were right medial striatum and left anterior striatum.Conclusion: The increased uptake of 11C-CFTin LRRK2-KO mice indicates the enhancive expression of DAT while the decreased uptake in G2019S-LRRK2 transgenic mice indicates the deduction. These results bidirectionally validated the effect of LRRK2 mutation on DAT expression. Acknowledgements: This research project was supported by the National Natural Science Foundation of China (No. 81571345, 81801752,81771179 ).

Synthesis and Preliminary Evaluation of [C-11]GNE-1023 As a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson's Disease

Preclinical Evaluation of Novel Positron Emission Tomography (PET) Probes for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2)

18F-Labelled pyrrolopyrimidines reveal brain leucine-rich repeat kinase 2 expression implicated in Parkinson’s disease

Radiosynthesis and Evaluation of 4-(6-[18f]fluoro-4-(5-isopropoxy-1h-indazol-3-yl)pyridin-2-yl)morpholine As a Novel Radiotracer Candidate Targeting Leucine-Rich Repeat Kinase 2.

Synthesis And Initial In Vivo Studies With [C-11]Sb-216763: The First Radio Labeled Brain Penetrative Inhibitor Of Gsk-3

Changes of Dopamine Transporter Detected by 11C-CFT PET in LRRK2-knockoutand G2019 Transgenicmice

Synthesis and Initial in Vivo Studies with [(11)C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3.

Synthesis and preliminary evaluation of novel PET probes for GSK-3 imaging

Discovery of potent LRRK2 inhibitors by ensemble virtual screening strategy and bioactivity evaluation

Radiosynthesis and Preliminary in Vivo Studies with [11C]SB216763: the First Brain Penetrative PET Tracer for Imaging of Glycogen Synthase Kinase-3 (GSK-3)

Development of Pyridothiophene Compounds for PET Imaging of α‐Synuclein

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives

Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission

Design, Synthesis and Identification of N, N-dibenzylcinnamamide (DBC) Derivatives As Novel Ligands for Α-Synuclein Fibrils by SPR Evaluation System.

The Development and Evaluation of a Novel Highly Selective PET Radiotracer for Targeting BET BD1

Development of a Candidate 11C-Labeled Selective Phosphodiesterase 1 Radioligand for Positron Emission Tomography

Leucine-rich repeat kinase 2 (LRRK2) inhibition upregulates microtubule-associated protein 1B to ameliorate lysosomal dysfunction and parkinsonism

Structure-Based Discovery of a 4,5-Dihydropyrazole-Cored PET Ligand for Imaging of Receptor-Interacting Serine/Threonine-Protein Kinase 1 (RIPK1) in the Brain

Radiosynthesis and Preclinical Evaluation of an 18F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A)

GTP‐binding inhibitors increase LRRK2‐linked ubiquitination and Lewy body‐like inclusions